Belfast-based healthtech startup B-Secur raises £8.8M funding to grow further


A healthtech startup B-Secur from Belfast represents the next generation of internal biometrics. In a recent development, the company has announced that it has completed a total raise of £8.8 million in 2021. The latest round was led by US-based First Capital Ventures and The Bank of Ireland Kernel Capital Growth Fund NI, thereby increasing its investment level to £2.2 million with other existing investors also participating in the round.

Growth plans

The funding will be used to cement the company’s traction in the wearable space whilst accelerating entry into the medical device market. The company, which has offices within Belfast’s Innovation Centre, Catalyst, employs over 45 scientists and engineers and will look to hire additional staff in Belfast and the US.

“The world-class team at B-Secur has demonstrated that their patented and FDA cleared technology delivers insights and value to wellness and medical devices alike. Kernel Capital are pleased to continue our strong support of the company as it accelerates its growth.” said Siggi Saevarsson, Partner, Kernel Capital.

“We are delighted with the investment by First Capital Ventures and by the continued support from Kernel Capital and our other investors and we look forward to a transformational 2022 when our technology will be embedded across both consumer and medical devices.” said Alan Foreman, CEO, B-Secur.

Patented ECG technology

B-Secur has developed the world’s first software technique that uses an individual’s unique heartbeat pattern, known as electrocardiogram (ECG) in everyday technologies to securely identify, and provide health and wellness insights at the same time. Medical grade ECG recording traditionally happens in the hospital environment using expensive equipment, but B-Secur are embedding this into latest smartwatches, cars and even clothing and are already selling to some of the world’s largest technology companies.

Last year, B-Secur was granted FDA clearance for its technology and has since signed its first contract with a US-based medical device manufacturer.